Investment Rating - The report maintains an "Outperform" rating for Yum China Holdings [2][7] Core Insights - Yum China held its 2025 Investor Day on November 17, launching the "RGM 3.0" strategy, focusing on resilience, growth, and competitive advantage, with innovation and efficiency as dual drivers [3][13] - The company targets over 30,000 stores by 2030, with specific store count goals of 20,000 by 2026 and 25,000+ by 2028 [4] - Revenue projections for 2025-2027 are USD 11.63 billion, USD 12.16 billion, and USD 12.76 billion, with year-over-year growth rates of 2.9%, 4.6%, and 4.9% respectively [7][14] Financial Projections - Adjusted net profits are expected to be USD 911 million in 2025, USD 1.03 billion in 2026, and USD 1.13 billion in 2027, with growth rates of 0.0%, 12.8%, and 10.2% respectively [7][14] - The company anticipates a gross profit margin (GPM) of 68.7% in 2025, increasing to 69.9% by 2027 [10][12] - The report projects a diluted EPS of USD 2.52 for 2025, increasing to USD 3.13 by 2027 [10][12] Expansion Strategy - Franchise empowerment is a core strategy, with plans to open over 3,000 new franchise stores from 2026 to 2028, with franchise stores making up 40%-50% of new openings for both KFC and Pizza Hut [4] - The company aims to enhance restaurant profitability, targeting an operating profit margin of at least 11.5% by 2028 [4] New Business Developments - New business initiatives, including KFC Coffee and KPRO, are expected to exceed initial growth expectations, with KFC Coffee projected to surpass 5,000 stores by 2029 [5] - The company plans to return approximately 100% of free cash flow to shareholders starting in 2027, with expected annual shareholder returns of USD 900 million to USD 1 billion [5]

Investment Rating - The investment rating for the company is "Buy" [1][7] Core Views - The company reported a total revenue of HKD 8.241 billion for the fiscal year ending September 30, 2025, representing a year-on-year decrease of 2.7% [2] - The net profit attributable to the parent company was HKD 1.146 billion, showing a year-on-year increase of 0.6% [2] - The company plans to distribute an interim dividend of HKD 0.15 per share, with a payout ratio of 50.80% [2] Revenue Analysis - Domestic sales in China reached HKD 4.675 billion, down 6.0% year-on-year, but the decline has significantly narrowed compared to the previous year [3] - The company is focusing on optimizing its product mix and enhancing collaboration with distributors to improve sales performance [3] - The overseas market showed resilience, with North America generating HKD 2.161 billion in revenue, up 0.3% year-on-year, and Europe and other markets achieving HKD 0.765 billion, up 4.3% [3] Product Performance - Revenue from sofas and related products was HKD 5.550 billion, down 4.6% year-on-year, while bedding and related products saw a decline of 7.4% [4] - Other products, including smart furniture, generated HKD 0.931 billion, up 11.4% year-on-year, primarily due to growth in overseas sales [4] Profitability - The company's gross margin and net margin were 40.4% and 14.2%, respectively, reflecting increases of 0.9 percentage points and 0.5 percentage points year-on-year [5] - The improvement in profitability is attributed to effective cost control and a decrease in raw material costs [5] Investment Recommendations - The company is positioned in a large consumer market with significant growth potential, and there is optimism regarding the stability of domestic sales and the recovery of international sales [6] - Revenue forecasts for FY2026 to FY2028 are projected at HKD 17.352 billion, HKD 18.527 billion, and HKD 19.855 billion, respectively [6] - The expected earnings per share (EPS) for the same period are HKD 0.57, HKD 0.61, and HKD 0.65, with corresponding price-to-earnings (PE) ratios of 8, 8, and 7 times [7]

Investment Rating - The report maintains a rating of "Buy" for the company [3] Core Views - The company plans to issue up to 800 million shares, representing no more than 11.52% of the post-issue share capital, and will list on the Shenzhen Stock Exchange [1][6] - The company is expected to achieve positive cash flow starting in 2024, with projected free cash flow of approximately 4 billion RMB, marking the first positive cash flow since 2003 [6] - The company is focusing on cost reduction and efficiency improvements, with a significant increase in dividends and expectations for value reassessment due to the upcoming share issuance [6] Financial Data and Valuation - Revenue projections for the company show a decline from 32,495 million HKD in 2023 to 29,397 million HKD in 2025E, with a year-on-year growth rate of -14%, -7%, and -3% respectively [2][10] - Operating profit is expected to decrease from 10,473 million HKD in 2023 to 8,138 million HKD in 2025E, with corresponding year-on-year growth rates of -1%, -17%, and -7% [2][10] - Net profit is projected to decline from 4,429 million HKD in 2023 to 3,337 million HKD in 2025E, with year-on-year growth rates of -4%, -24%, and -1% [2][10] - The company’s price-to-earnings (P/E) ratio is forecasted to be 9.1x in 2025, decreasing to 7.9x by 2027 [2][10] Shareholder Information - The major shareholder is China Everbright Group Co., Ltd., holding a 43.08% stake in the company [3] Market Performance - The company's stock price has shown an absolute performance increase of 46% over the past 12 months [5]

Investment Rating - The report maintains a "Buy" rating for InnoCare Pharma [8][16] Core Insights - InnoCare Pharma's revenue for the first three quarters of 2025 increased by 60% year-on-year, reaching RMB 1.12 billion, with a net loss of RMB 64 million, which is a 77% year-on-year reduction [5][12] - The company has raised its sales target for its key product, orelabrutinib, from over 35% year-on-year growth to over 40% for 2025, following strong sales performance [6][13] - The company has a robust pipeline for both liquid tumors and autoimmune diseases, with several products in various stages of development [7][14][15] Financial Performance - For the first three quarters of 2025, orelabrutinib sales reached RMB 1.01 billion, a 46% increase year-on-year, with third-quarter sales of RMB 373 million, reflecting a 35% year-on-year and 14% quarter-on-quarter growth [5][12] - Research and development expenses for the first three quarters of 2025 were RMB 676 million, a 10% increase year-on-year, while selling expenses rose by 41% to RMB 386 million [5][12] - As of September 2025, the company had approximately RMB 7.76 billion in cash on hand [5][12] Future Outlook - The company plans to submit a New Drug Application (NDA) for orelabrutinib for the treatment of ITP in the first half of 2026 and expects to read out phase IIb data for SLE by the end of 2025 [7][14] - InnoCare Pharma anticipates submitting 5-7 IND applications targeting malignant tumors and autoimmune diseases in 2026 [15]

Investment Rating - The investment rating for Tencent Holdings is "Buy" and is maintained [7]. Core Views - Tencent's Q3 2025 revenue reached 192.9 billion yuan, a year-on-year increase of 15% and a quarter-on-quarter increase of 5%. Operating profit was 63.6 billion yuan, up 19% year-on-year. Non-IFRS net profit attributable to shareholders was 70.6 billion yuan, an 18% increase year-on-year. Both revenue and adjusted net profit exceeded market expectations [2][4]. Revenue Breakdown - The revenue growth was driven by: 1. Strong performance from both new and existing games, with overseas game revenue and growth rates hitting record highs. Domestic game revenue grew 15% to 42.8 billion yuan, while overseas game revenue increased by 43% to 20.8 billion yuan, marking a record-breaking quarter [7]. 2. AI technology enhancements and strong internal demand led to accelerated growth in advertising revenue, which rose 21% year-on-year to 36.2 billion yuan [7]. 3. Recovery in commercial payments and AI-driven growth in cloud service revenue contributed to a 10% year-on-year increase in financial technology and enterprise service revenue, totaling 58.2 billion yuan [7]. R&D and Profitability - Tencent's R&D investment reached a record high, with Q3 R&D spending at 22.8 billion yuan, an increase of 28% year-on-year. The gross margin for Q3 was 56.4%, reflecting a year-on-year increase of 3.3 percentage points [7]. Capital Expenditure - Capital expenditure in Q3 decreased by 24% year-on-year to 13 billion yuan, accounting for approximately 10.7% of revenue for the first three quarters [7].

Investment Rating - The report maintains a "Buy" rating for the company [1][7][15] Core Insights - The company has raised its 2025 sales target from a year-on-year growth of over 35% to over 40% due to strong sales performance of its key product, orelabrutinib, which saw a 46% year-on-year increase in sales to RMB 1.01 billion in the first three quarters of 2025 [4][5][12] - The company reported a revenue of RMB 1.12 billion for the first nine months of 2025, reflecting a 60% year-on-year growth, with a net loss of RMB 64 million, which is a 77% reduction compared to the previous year [4][11] - The company has a robust pipeline in both oncology and autoimmune diseases, with several products in various stages of development, including orelabrutinib and ICP-332 [5][6][13][14] Financial Performance - For the first three quarters of 2025, the company recorded a revenue of RMB 1.12 billion, with a net loss of RMB 64 million, and a third-quarter revenue of RMB 384 million, marking a 38% year-on-year increase [4][11] - Research and development expenses for the first three quarters were RMB 676 million, a 10% increase year-on-year, while selling expenses rose by 41% to RMB 386 million [4][11] - The company had approximately RMB 7.76 billion in cash as of September 2025, providing a solid financial foundation for ongoing and future projects [4][11] Sales and Product Development - Orelabrutinib's sales reached RMB 373 million in the third quarter of 2025, with a year-on-year growth of 35% and a quarter-on-quarter growth of 14% [5][12] - The company is advancing its autoimmune pipeline, with plans to submit a new drug application for orelabrutinib for ITP in the first half of 2026 and to read out phase IIb data for SLE by the end of 2025 [6][13] - The company expects to submit 5-7 IND applications targeting malignant tumors and autoimmune diseases in 2026, indicating a strong early-stage pipeline [14]

Investment Rating - The report maintains a "Buy" rating for Tencent Music-SW (01698) [1] Core Insights - The increase in ARPPU has driven subscription revenue growth, while non-subscription business has achieved breakthroughs [2][6] - For Q3 2025, the company reported revenue of 8.46 billion yuan, a year-over-year increase of 20.6%, and a net profit attributable to shareholders of 2.15 billion yuan, up 36% year-over-year [6][11] Financial Performance - Q3 2025 revenue of 8.46 billion yuan, with a year-over-year growth of 20.6% and a quarter-over-quarter growth of 0.2% [6] - Net profit attributable to shareholders reached 2.15 billion yuan, reflecting a year-over-year increase of 36% [6] - Non-GAAP net profit was 2.48 billion yuan, up 28% year-over-year [6] - Operating costs increased by 18.8% year-over-year, primarily due to rising costs in offline performances, IP-related expenses, and advertising agency fees [6] - Gross margin stood at 43.5%, with a year-over-year increase of 0.9 percentage points [6] Business Segmentation - Online music service revenue for Q3 2025 was 6.97 billion yuan, a year-over-year increase of 27.2% [7] - Subscription revenue within online music reached 4.5 billion yuan, up 17.2% year-over-year [7] - Non-subscription revenue surged to 2.47 billion yuan, a year-over-year increase of 50.6% [7] User Metrics - The number of paid users reached 126 million, a year-over-year increase of 6% [7] - The ARPPU for Q3 2025 was 11.9 yuan, reflecting a year-over-year increase of 10% [7] Future Projections - Revenue forecasts for 2025-2027 are 32.98 billion yuan, 36.86 billion yuan, and 40.73 billion yuan respectively [11] - Projected net profit for the same period is 11.13 billion yuan, 9.84 billion yuan, and 11.16 billion yuan respectively [11] - The report anticipates continued growth driven by an increase in paid users and ARPPU, alongside strong performance in non-subscription business [11]

Investment Rating - The investment rating for the company is "Buy" [7][17]. Core Insights - The company has conducted a placement of 49.5 million shares at a price of HKD 41.70 per share, which represents 2.17% of the total share capital. This placement is expected to enhance liquidity and attract institutional investors [5][14]. - The company is projected to maintain a strong sales performance, ranking among the top three in the industry, with a focus on acquiring high-quality land in core first and second-tier cities [5][15]. - The company's shopping center operations are expanding steadily, with notable performance in lower-tier markets, indicating a robust operational capability and brand influence [5][16]. - Revenue and net profit forecasts for the company from 2025 to 2027 are expected to show consistent growth, with net profits projected at HKD 40.73 billion, HKD 45.54 billion, and HKD 51.05 billion respectively [5][17]. Summary by Sections Placement and Liquidity - The placement by the controlling shareholder, China Resources Land, aims to diversify the shareholder structure and improve stock liquidity, with expected proceeds of approximately HKD 20.61 billion for land acquisition and operational costs [5][14][15]. Sales Performance and Land Acquisition - For the period from January to October 2025, the company achieved a cumulative sales amount of HKD 169.6 billion, reflecting a year-on-year decline of 16.6%, consistent with the industry's performance. The land acquisition amount was HKD 33.4 billion, showing a year-on-year increase of 37.6% [5][15]. Shopping Center Expansion - As of the first half of 2025, the company operates 125 shopping centers, with six new openings in the third quarter. The expansion includes both first-tier cities and lower-tier cities, demonstrating the company's competitive advantage in operational capabilities [5][16]. Financial Projections - The company’s revenue is projected to grow from HKD 184.97 billion in 2025 to HKD 221.53 billion in 2027, with corresponding net profits increasing from HKD 40.73 billion to HKD 51.05 billion [5][17][18].

Investment Rating - The report assigns a "Buy" rating for the company, marking it as a first-time coverage due to its position as a global leader in pearlescent pigments and the potential underestimation of its performance [6][9]. Core Insights - The company has established itself as a leader in the global pearlescent pigment industry through strategic acquisitions, including the integration of Korean CQV and German Merck's surface solutions business (SUSONITY), which positions it well for future growth [8][11]. - The report highlights the high growth potential of the pearlescent pigment market, driven by increasing demand in high-end applications such as cosmetics and automotive coatings, with a projected CAGR of 13.99% from 2016 to 2023 [48][54]. - The company is expected to see significant revenue growth, with projected revenues of RMB 3.52 billion in 2025, reflecting a year-on-year growth rate of 114.85% [7][9]. Summary by Sections Company Overview - The company, originally founded as Guangxi Qise Pearlescent Effect Materials Co., Ltd. in 2011, has grown to become a global leader in pearlescent pigments, successfully listing on the Hong Kong Stock Exchange in 2021 and expanding its global footprint through acquisitions [17][24]. Financial Performance - The company has maintained a strong revenue growth trajectory, with a CAGR of 36.58% from 2017 to 2024, and an increase in gross margin from 43.99% in 2017 to 53.34% in 2024 [32][37]. - The report forecasts net profits of RMB 1.91 billion, RMB 5.29 billion, and RMB 10.05 billion for 2025, 2026, and 2027, respectively, with corresponding P/E ratios of 41, 15, and 8 [9][10]. Market Dynamics - The pearlescent pigment industry is characterized by high growth potential, low price sensitivity, and strong brand loyalty, making it a unique investment opportunity [11][45]. - The report emphasizes the importance of synthetic mica as a superior alternative to natural mica, addressing supply chain challenges and enhancing product quality [67][74]. Growth Drivers - Key growth drivers include the successful integration of acquired brands, expansion of production capacity, and the increasing demand for high-end applications in cosmetics and automotive sectors [8][11][61]. - The company plans to expand its domestic production capacity to approximately 48,700 tons, which is expected to support revenue growth and improve operational efficiency [61][79]. Competitive Landscape - The competitive landscape is dominated by major players such as Merck and BASF, with the company positioned to capture market share through its strategic acquisitions and product innovations [54][56]. - The report notes that the high-end market for pearlescent pigments is characterized by significant barriers to entry, making it difficult for new brands to penetrate [54][56].

Investment Rating - The report assigns a "Collect" rating to CK Infrastructure Holdings, with a target price of HKD 60.35 based on a 17x PE for 2026 [3]. Core Insights - CK Infrastructure Holdings demonstrates stable business performance, with an expected increase in project return rates during the new regulatory period [2][31]. - The company is actively expanding sustainable development projects in the UK and Australia, including smart grid solutions and electric vehicle charging infrastructure [2]. - The financial forecasts predict net profits of HKD 85.97 billion, HKD 89.38 billion, and HKD 92.69 billion for 2025, 2026, and 2027 respectively, reflecting a growth trend [3][5]. Business Performance Summary - For the first half of 2025, the company reported stable performance across various segments, with contributions from Electric Power Industry Limited increasing by 1% year-on-year to HKD 1.095 billion [4][11]. - The UK operations contributed HKD 2.223 billion, a 19% increase year-on-year, primarily due to the performance of Northumbrian Water and several gas networks [4][11]. - The Australian infrastructure business saw a decline of 8% in profit contribution to HKD 793 million, attributed to currency fluctuations and the expiration of profitable contracts [4][11]. - The company’s financial foundation remains strong, with cash holdings of HKD 47 billion and a net debt to total capital ratio of 10.6% [14][15]. Regulatory Period Insights - The new regulatory period starting April 1, 2026, is expected to enhance return rates for UK operations, with Northumbrian Water and Wales & West Utilities receiving proposals for increased returns [4][31]. - In Australia, significant regulatory resets are anticipated in 2025, with SA Power Networks commencing a new regulatory period on July 1, 2025, which is expected to allow for increased returns and asset base growth [4][34]. Dividend Information - The interim dividend for 2025 is set at HKD 0.73 per share, marking a 1.4% increase year-on-year, continuing a 28-year streak of dividend growth since the company's listing [4][11].